CDC finds lower RSV hospitalization rates for infants receiving prevention products
The Centers for Disease Control and Prevention May 8 released an analysis that found declines in hospitalizations for infants infected with respiratory syncytial virus during the 2024-2025 RSV season — the first with widespread availability of the maternal RSV vaccine and nirsevimab, a long-acting monoclonal antibody. Rates were 45% to 52% lower for infants less than 3 months old and 28% to 43% lower for those less than 8 months old. As of February, an estimated 66% of infants received either the maternal RSV vaccine or nirsevimab during the 2024-2025 season.
Related News Articles
Headline
In this conversation, Tori Bahr, M.D., section chief of pediatrics at Gillette Children’s, shares how healthcare teams can improve the transition from…
Headline
As part of the AHA’s Opportunities for Innovations in Rural Maternal Care initiative, a recent Commonwealth Fund blog discusses strategies hospitals can use to…
Headline
The Health Resources and Services Administration Maternal and Child Health Bureau has released the latest data from the National Survey of Children’s Health.…
Headline
In a new blog by Aisha Syeda, senior program manager at AHA, learn how you can participate in the first Better Health for Mothers and Babies Awareness Week,…
Blog
Every mother and baby deserves the opportunity for a healthy start. Hospitals and health systems help make that possible by providing care throughout pregnancy…
Headline
A report released Sept. 21 by the Centers for Disease Control and Prevention found improvements in mental health and dietary habits among U.S. high school…